Association of cyclophosphamide drug–metabolizing enzyme polymorphisms and chemotherapy-related ovarian failure in breast cancer survivors

H. Irene Su(University of California San Diego), Angela DeMichele(University of Pennsylvania), Mary D. Sammel(Colorado School of Public Health), Michelle Horn(University of Pennsylvania), Clarisa R. Gracia(Beijing Obstetrics and Gynecology Hospital), Luke Velders(University of Pennsylvania), Jennifer M. Matro(University of Pennsylvania), Corrie A. Stankiewicz(University of Pennsylvania), Jamie Green(University of Pennsylvania)
Fertility and Sterility
April 20, 2009
10.1016/j.fertnstert.2009.03.034
Cited by 64

Related Papers

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
|The Lancet Oncology|2016|1.8k
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
|New England Journal of Medicine|2018|1.3k
Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer
|JAMA Oncology|2020|707
Exosome RNA Unshielding Couples Stromal Activation to Pattern Recognition Receptor Signaling in Cancer
|Cell|2017|448
(untitled)
|Edinburgh Research Explorer|0|353